Lilly Pushes Effient As Cost-Effective

Eli Lilly has published results showing oral antiplatelet Effient (prasugrel) to be more cost-effective than Plavix (clopidogrel). The US firm contends that the results of a health economic sub-study of the TRITON-TIMI 38 clinical trial, published in Circulation[1] showed Effient, which was developed and is co-promoted by Daiichi Sankyo, was more cost-effective, and in most cases cost saving among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting. BMI believes these study results will form a key part of Lilly's marketing campaign and will be used to make a strong case to healthcare professionals and

To read the full article, please choose one of the following options: